Hyperguides

Orthopaedics / Paediatric orthopaedics

Charcot-Marie-Tooth Disease

Charcot-Marie-Tooth Disease Tutorial Henry Boucher, MD
Article


History

The first cases of Charcot-Marie-Tooth disease (CMT) were reported in 1855 by Aran and Virchow. They described patients with lower extremity weakness followed by upper extremity involvement. In 1886, Charcot and Marie, simultaneously with Tooth, published on the disease bearing their names.1

Classification

CMT is the prototype disease of the numerous hereditary motor sensory neuropathies (HMSN). The HMSNs are classified into 7 types, with I, II, and III particular to pediatric orthopedics.2,3 The other types of HMSNs occur later in life.

Type Classification
I The hypertrophic form of CMT, also known as Roussy-Levy disease. It has autosomal dominant inheritance. Clinically, it is a demyelinating disease with distal extremity weakness, no DTR, and slow motor NCV.
II The neuronal form of CMT. This type has a variable inheritance. Clinically, this form is less severe than type I and displays a mild decrease in NCVs and present DTRs. The onset of disease is later than type I.
III Also known as Déjerine-Sottas disease, this type has an autosomal recessive inheritance. This is a more severe type of CMT that begins in infancy and is associated with severe loss of motor and sensory function. This is also a demyelinating disease with no distal DTRs.
IV Known as Refsum's disease, this type is characterized by excessive phytanic acid (a fatty acid).
V Clinical features include a neuropathy with spastic paraplegia.
VI Components include optic atrophy with peroneal muscle atrophy
VII Patients display distal muscle weakness and atrophy, along with retinitis pigmentosa.
Abbreviations: CMT=Charcot-Marie-Tooth Disease, DTR=Deep tendon reflexes, and NCV=Nerve conduction velocities.

Genetics

HMSN I results from a duplication or point mutation of part of the short arm of chromosome 17. This is where the human peripheral myelin protein-22 resides.2,3

Clinical Features

The diagnosis of CMT is made by physical exam, family history, and ancillary tests. The tests include electromyography (EMG), nerve conduction velocity (NCV), and muscle and peripheral nerve biopsy. The patient may present with shoe-wear difficulty, abnormal walking, or a foot deformity. On exam, the patient may display a cavo-varus foot deformity, distal muscle wasting, weakness of the foot and ankle, and decreased sensation and proprioception.1 The Coleman block test (1977) is used to evaluate for hindfoot rigidity. A 1-inch block is placed under the heel and lateral foot to neutralize the flexed first metatarsal. If the hindfoot is supple, it should not remain in varus.4 It is also important to examine the hips, spine, and upper extremities. Radiographs will confirm the cavovarus, and one can look at Meary's angle (the angle between the first metatarsal and the talus) on a lateral foot film. This angle is normally 0°.

An EMG displays increased amplitude and duration, indicative of a neuropathic process. Motor and sensory NCV shows decreased conduction velocity. Muscle biopsy displays diffuse atrophy with replacement of muscle fibers with fibrous and adipose tissue. Nerve biopsy is significant for loss of myelinated fibers and increased fibrous tissue in the endoneurium and perineurium. Enzyme analysis (alkaline phosphate, creatinine phosphokinase, lactic dehydrogenase, and serum glutamic oxalacetic transaminase) in a kinship study showed no recognizable pattern, therefore, it is not believed to be helpful.

Pes cavus is the most apparent clinical deformity of the lower extremity in CMT. However, it can occur in multiple neurologic conditions such as cerebral palsy, polio, Friedreich's ataxia, arthrogryposis, and lesions affecting the conus or cauda equina. The elements of pes cavus in CMT include claw toes, a plantar flexed first metatarsal, a pronated forefoot, a high medial arch, and hindfoot varus. The process begins with progressive interosseous and lumbrical weakness, which leaves the toe flexors and extensors unopposed. This leads to metatarsophalangeal (MTP) joint hyperextension, and interphalangeal (IP) joint flexion (claw toes). The plantar intrinsic muscles shorten and fibrose, producing a "windlass effect." The plantar fascia contracts, and the first metatarsal plantar flexes. This all leads to a forefoot in equinus and pronation (medial rays more plantar flexed) with an elevated medial arch.1,4,5 The hindfoot swings into varus, both to counteract the forefoot pronation and to greater power the inverter muscles. The soft tissues continue to contract leading to a rigid deformity. Callosities can develop under the metatarsal heads and lateral foot. Ankle instability develops secondary to abnormal weight bearing, weakness, and decreased proprioception.1-4 Muscle atrophy follows a pattern, with the muscles supplied by the longest axons degenerating first. The calf musculature retains its bulk and power longer. All sensory modalities are affected.1

Upper extremity involvement has a later onset (about 20 years of age) and tends to be less severe, although 50% to 65% of CMT patients have involvement. Intrinsic muscle weakness leads to decreased dexterity, and patients also have progressive sensory loss. Loss of strength and sensation are the most common complaints. Upper extremity physical examination reveals intrinsic wasting and low median and ulnar nerve palsies. Strength seems to deteriorate over the first 10 years and then stabilize, however, dexterity continues to decline.6 Soft tissue procedures may be helpful for functional improvement, for example tendon transfer for opposition and arthrodesis to prevent metacarpophalangeal hyperextension.2,3

Associated Conditions

  1. Hip dysplasia is present in approximately 6% to 10% of those with HMSN and presents at a later age than usual.
  2. Scoliosis is present in approximately 10% of patients and is more common in females with HMSN I. It is treated like idiopathic scoliosis, but the patients' curves may have a more significant kyphotic element. Intra-operative somatosensory evoked potential may not display signals, therefore, a wake-up test is required to assess for iatrogenic neurologic damage.2

Treatment

The goal of treatment is a flexible, straight, plantigrade foot. Treatment begins with soft tissue procedures, unless there is rigidity.

Options For Surgery
  1. Soft tissue procedures:
    1. Claw toe correction: Flexor digitorum longus to extensor hood transfer (Girdlestone-Taylor) or extensor release with interphalangeal (IP) joint fusion, and/or the Jones procedure (extensor hallucis longus to first metatarsal head and IP joint fusion) for the great toe.
    2. Plantar release: Recommended for forefoot cavus. Structures to release include the plantar fascia, flexor digitorum brevis, quadratus plantae, abductor hallucis, abductor digiti quinti, knot of Henry. Lengthen the toe flexors.
    3. Plantar medial release: Recommended for forefoot cavus and supple hindfoot varus. Release tendon sheaths of the posterior tibialis, flexor hallucis longus, flexor digitorum. Incise T-N capsule and superficial deltoid.
    4. Tendon transfers: Recommended for muscle balance. Anterior or posterior tibialis to dorsum of foot for weak eversion and dorsiflexion.
  2. Osteotomies:
    1. Calcaneal osteotomy: Recommended for rigid hindfoot varus, in conjunction with soft tissue releases.
    2. Midtarsal osteotomy: Recommended for rigid cavus. Dorso-lateral closing wedge removed from cuneiform and cuboid.
  3. Fusion:
    1. Triple arthrodesis: Recommended salvage procedure in mature patients with stiff, painful, and non-functional foot.

General Principles

In children younger than 8 years old with a supple hindfoot, soft tissue procedures are recommended. In patients with a rigid hindfoot younger than 12 years old, calcaneal osteotomy with a plantar-medial release is recommended. Reserve triple arthrodesis for children with rigid feet who are older than 12 years old.4 One study showed positive results at an average 14-year follow up for soft tissue procedures in patients with CMT. A positive result was achieved if the patient did not require a triple arthrodesis, and was pleased with the appearance and function of the foot. Another study on long-term follow up (average 21 years) of triple arthrodesis indicated that this should be a salvage procedure since almost 50% have poor long-term results. A poor result meant inadequate correction, poor gait, moderate to severe pain, pseudoarthrosis, need for orthosis, limited activities, and arthritis. The most common complication in the study was arthritis of the ankle and midfoot. Residual deformity was present in 9 out of 30 feet.5

References

  • Sabir M, Lyttle D. Pathogenesis of Charcot-Marie-Tooth disease. Clinical Orthop. 1984; 184:223.
  • Morrissy RT, Weinstein SL. Lovell and Winter's Pediatric Orthopaedics. 4th ed. Philadelphia: Lippincott-Raven, 1996:561.
  • Shapiro F, Specht L. The diagnosis and orthopaedic treatment of childhood spinal muscular atrophy, peripheral neuropathy, Friedreich ataxia, and arthrogryposis. J Bone Joint Surg. 1993; 75A:1699.
  • McCluskey WP, Lovell WW, Cummings RJ. The cavovarus foot deformity: Etiology and management. Clinical Orthop. 1989; 247:27.
  • Wetmore RS, Drennan JC. Long-term results of triple arthrodesis in Charcot-Marie-Tooth disease. J Bone Joint Surg. 1989; 71A:417.
  • Miller MJ, et al. The hand in Charcot-Marie-Tooth disease. J Hand Surg. 1991; 16B:191.